Rentschler Biopharma Takes First Steps in US Expansion Project
Rentshler Biopharma has begun its expansion project in the United States by putting a single-use bioreactor into operation at the Milford facility in Massachusetts.
Rentshler Biopharma, a contract development and manufacturing organization (CDMO) headquartered in Germany, has begun its expansion project in the United States by putting a single-use bioreactor into operation at the Milford facility in Massachusetts.
In a Nov. 6, 2019 press release, the company announced that the XDR-500 bioreactor, which has a working volume of 100–500 L and downstream capabilities of 2–8 g/L, will be part of the good manufacturing practice (GMP) facility suite concept. The company anticipates that the system will be ready for clients by mid-2020, and it is currently being prepared for technology transfer.
Additionally, Rentshler Biopharma revealed some other expansion plans, including another building for large-scale manufacturing, which will also be single-use bioreactor manufacturing and will feature lab capacity for new modalities. Through its client-centric approach, the company aims to facilitate robust and scalable production of complex biomolecules in both Europe and the US.
Source: Rentschler Biopharma
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
